261
￭ S-443 ￭
Nilotinib-induced interstitial lung disease
1Division of Hematology-Oncology, Department of Internal Medicine, Gyeongnam Regional Cancer Center, Institute of Health Sciences, Gyeongsang National University School of Medicine, 2Department of Pathology, Institute of Health
Sciences, Gyeongsang National University School of Medicine
*
Un Seok Lee
1, Se-Il Go
1, Won Sup Lee
1, Gyeong-Won Lee
1, Jung Hun Kang
1, Myung Hee Kang
1, Jeong-Hee Lee
2, Hoon-Gu Kim
1Nilotinib is a second-generation tyrosine kinase inhibitor active in patients with chronic myeloid leukemia (CML) resistant to imatinib, and has been recently approved for newly diagnosed patients. We present a case of nilotinib-induced interstitial lung disease (ILD). A 67-year-old female patient was initially treated with imatinib for chronic-phase Philadelphia chromosomepositive (Ph+) CML. Imatinib was replaced by nilotinib because of hematological toxicity. The patient had received nilotinib for about 3 years without significant adverse effects. She visited the clinic due to chronic cough; chest X-ray revealed consolidations in both lung fields. Nilotinib-induced ILD was diagnosed based on intensive workup, including lung biopsy. She responded dramatically to corticosteroid therapy. To our knowledge, this is the first reported case of nilotinib-induced ILD in a patient with Ph+ CML. We emphasize that if unexplained lung abnormalities progress in patients receiving nilotinib, physicians should consider this potentially fatal complication in their differential diagnoses.
￭ S-444 ￭
Clinical Characteristics,Pathological Distribution and Prognostic Factors in NHL of Waldeyer's Ring
1Department of Internal Medicine, Pusan national University Hospital Medical Research Institute, Busan, 2Department of Internal Medicine, Seoul Asan Hospital, Seoul, 3Department of Internal Medicine, Dankook University Hospital, Cheonan,
4Department of Internal Medicine, Seoul Samsung Hospital, Seoul, 5Department of Internal Medicine, Busan Baik Hospital, Busan, 6Department of Internal Medicine, Hallym University Medical Center, Seoul, 7Department of Internal Medicine, Korea
University Hospital, Seoul, 8Department of Internal Medicine, Severance Hospital, Seoul, Korea.
*
SeongJun Lee
1, Cheolwon Suh
2, Soonil Lee
3, Wonseog Kim
4, Wonsik Lee
5, Hyojung Kim
6, Chulwon Choi
7, Jinseok Kim
8, Hojin Shin
1Background/Aims: In Asia, the incidence of non-Hodgkin’s lymphoma (NHL) has increased in recent decades. Waldeyer’s ring (WR) is the most common site of NHL involving the head and neck. In this study, pathological distribution of WR-NHL and its clinical features were retrospectively analyzed. Methods: From January 2000 through December 2010, we analyzed the medical records of 328 patients from nine Korean institutions who were diagnosed with WR-NHL. Results: The study group comprised 197 male and 131 female patients with a median age of 58 years (range: 14-89). The percentage of localized disease (stage I/II) was 64.9%, and that of low risk disease (low/low-intermediate by International prognostic index) was 76.8%. Diffuse large B cell lymphoma (DLBCL; 240 patients; 73.2%) was the most common pathologic subtype, followed by peripheral T cell lymphoma (14 patients; 4.3%), and nasal NK/T cell lymphoma (14 patients; 4.3%). WR-NHL occurred most frequently in the tonsil (199 patients, 60.6%). Extranodal involvement was higher in the T cell subtype (20 patients; 42.5%) compared to B cell subtype (71 patients; 25.2%). Multivariate analyses showed that age ≥ 62 years, T-cell subtype, and no complete remission were significant risk factors for overall survival. Conclusions: DLBCL was found to occur more frequently in Korea than the incidence reported by other WR-NHL studies. The T cell subtype lymphoma was more frequent than follicular lymphoma. T cell subtype lymphoma, age ≥ 62 years, and no complete remission after first line treatment were significant poor prognostic factors for overall survival by multivariate analysis.
Table 1. Multivariate analysis of prognostic factors for overall survival in patients with WR-NHL
Parameters HR (95% CI) p value
Age≥62 years 2.645 (1.427-4.904) 0.001
ECOG>1 0.903 (0.306-2.856) 0.906
B symptom (+) 0.983 (0.464-2.086) 0.800
Elevated serum LDH level 1.017 (0.788-1.312) 0.644
HBs Ag (+) 1.089 (0.409-2.901) 0.294
Anti HCV Ab (+) 6.380 (0.777-52.415) 0.081
EBV (+) 2.592 (0.897-7.483) 0.078
Extra-nodal site >1 1.214 (0.517-2.847) 0.711
T cell subtype 2.944 (1.410-6.147) <0.001
High-intermediate or high IPI 1.140 (0.770-1.688) 0.466
Advanced stage 1.333 (0.563-3.154) 0.637
No CR 1.536 (1.270-1.856) <0.001
